David Risinger

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its Q3 results, with the revenue 1 percent below consensus and the EPS missing the consensus forecast by 11 percent. Morgan Stanley’s David Risinger maintains an Overweight rating on the company, with a price target of $42. 3 Concerns The...

The Wall Street Journal reported that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) was in "advanced talks" to sell its gastroenterology unit to Takeda Pharmaceutical Co Ltd (OTC: TKPYY) for nearly $10 billion. A sale of Salix for that valuation appears to be a positive and represents...

Following meetings with the top management of Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Morgan Stanley’s David Risinger expressed confidence that management is “taking the right steps to turn the business around and pay down debt.” Risinger reiterated an Overweight rating on...

Financial concerns surrounding Valeant Pharmaceuticals Intl Inc (NYSE: VRX) should alleviate as the company renegotiates covenants and pays down debt, and “deleveraging should drive equity value accretion,” Morgan Stanley’s David Risinger said in a report. He upgraded the rating...

It seems like yesterday the Internet was about to break under the sudden scrutiny of drug pricing issues brought mainstream by Turing Pharma and its controversial leader Martin Shkreli. Valeant Pharmaceuticals Intl Inc (NYSE: VRX) ended up being the biggest publicly traded target, after Shkreli...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported a 1Q16 EPS miss and reduced its full-year guidance. Morgan Stanley’s David Risinger maintained an Equal-weight rating for the company, with a price target of $36. Analyst David Risinger commented that Valeant was a complex story with...

Pfizer Inc. (NYSE: PFE) has agreed to acquire Anacor Pharmaceuticals Inc (NASDAQ: ANAC) in a $5.2 billion deal, which adds an eczema gel to its portfolio. The news comes a month after the U.S. pharma major shelved plans to buy Allergan plc Ordinary Shares (NYSE: AGN). Morgan Stanley’s...

Allergan plc Ordinary Shares (NYSE: AGN) reported Q1 results with revenue below estimates but non-GAAP EPS beating expectations. Morgan Stanley’s David Risinger maintained an Overweight rating on the company, with a price target of $300. Allergan reported revenue of $3.8 billion, with...

While naming its new CEO, Perrigo Company plc Ordinary Shares (NYSE: PRGO) also lowered its 2016 guidance, within nine weeks of having issued it. Morgan Stanley’s David Risinger maintained an Equal-Weight rating on the company, while lowering the price target from $151 to $112, to reflect...

Shares of Horizon Pharma PLC (NASDAQ: HZNP) have surged 68 percent since November 27. Morgan Stanley’s David Risinger resumed coverage of the company with an Underweight rating and a price target of $23. Payers may exert greater pressure on the primary care business volume and net...

Shares of Mallinckrodt PLC (NYSE: MNK) are down 27 percent year-to-date. Morgan Stanley’s David Risinger upgraded the rating on the company from Equal-Weight to Overweight, while raising the price target from $74 to $88.> A recovery in Acthar sales indicates robust growth potential for the...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are now lower by 70 percent over the past three months. Analysts at Deutsche Bank and Morgan Stanley both raised concerns on the company's business. Gregg Gilbert of Deutsche Bank noted a propriety survey with doctors indicated...